Glenmark Pharmaceuticals Inc., USA, (Glenmark USA) has agreed to enter into a settlement with the putative direct purchaser class, for a total of $37.75 million. The settlement is subject to approval by the court overseeing the litigation. The settlement is payable in two instalments, with $11,100,000 due after preliminary approval by the Court and the second payment, $26,650,000, due on or before April 1, 2026.

The settlement makes clear that Glenmark USA denies each and every one of the allegations against it and the settlement is not on the basis of Glenmark USA having conceded or admitted any liability or illegality.

Glenmark USA is named in multiple antitrust and consumer protection lawsuits, including class actions, consolidated in the Eastern District of Pennsylvania, U.S. These relate to industry-wide allegations concerning price-fixing, market allocation, and related anticompetitive conduct.

Plaintiffs include putative classes of direct purchasers, end-payers, and indirect purchasers of generic drugs, as well as numerous private, direct-action plaintiffs. Plaintiffs allege both individual drug-specific conspiracies and an “overarching” conspiracy among manufacturers of generic drugs in the United States.

Glenmark USA continues to deny all allegations and has been defending these matters vigorously.